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Abstract 
Background: Rabies is preventable by pre‑ and/or post‑exposure prophylaxis consisting of series of rabies vaccina‑
tions and in some cases the use of immunoglobulins. The success of vaccination can be estimated either by measur‑
ing virus neutralising antibodies or by challenge experiment. Vaccines based on rabies virus offer cross‑protection 
against other lyssaviruses closely related to rabies virus. The aim was to assess the success of rabies vaccination meas‑
ured by the antibody response in dogs (n = 10,071) and cats (n = 722), as well as to investigate the factors influenc‑
ing the response to vaccination when animals failed to reach a rabies antibody titre of ≥ 0.5 IU/ml. Another aim was 
to assess the level of protection afforded by a commercial veterinary rabies vaccine against intracerebral challenge 
in mice with European bat lyssavirus type 2 (EBLV‑2) and classical rabies virus (RABV), and to compare this with the 
protection offered by a vaccine for humans.
Results: A significantly higher proportion of dogs (10.7%, 95% confidence interval CI 10.1–11.3) than cats (3.5%; 95% 
CI 2.3–5.0) had a vaccination antibody titre of < 0.5 IU/ml. In dogs, vaccination with certain vaccines, vaccination over 
6 months prior the time of antibody determination and vaccination of dogs with a size of > 60 cm or larger resulted in 
a higher risk of failing to reach an antibody level of at least 0.5 IU/ml. When challenged with EBLV‑2 and RABV, 80 and 
100% of mice vaccinated with the veterinary rabies vaccine survived, respectively. When mice were vaccinated with 
the human rabies vaccine and challenged with EBLV‑2, 75–80% survived, depending on the booster. All vaccinated 
mice developed sufficient to high titres of virus‑neutralising antibodies (VNA) against RABV 21–22 days post‑vaccina‑
tion, ranging from 0.5 to 128 IU/ml. However, there was significant difference between antibody titres after vaccinat‑
ing once in comparison to vaccinating twice (P < 0.05).
Conclusions: There was a significant difference between dogs and cats in their ability to reach a post vaccination 
antibody titre of ≥ 0.5 IU/ml. Mice vaccinated with RABV‑based rabies vaccines were partly cross‑protected against 
EBLV‑2, but there was no clear correlation between VNA titres and cross‑protection against EBLV‑2. Measurement 
of the RABV VNA titre can only be seen as a partial tool to estimate the cross‑protection against other lyssaviruses. 
Booster vaccination is recommended for dogs and cats if exposed to infected bats.
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Background
Rabies is a fatal encephalomyelitis caused by lyssaviruses. 
Rabies virus (RABV) causes about 99% of all rabies cases 
in humans, mostly in Asia and Africa. Even though the 
case fatality is almost 100%, the disease can be prevented 
by pre-exposure vaccination and by post-exposure treat-
ment shortly after exposure. Pre-exposure vaccination 
can prevent the disease, but booster vaccination upon 
exposure is required to ensure that the immune system 
responds optimally [1]. Thirteen other lyssavirus species 
have been accepted by the International Committee on 
Taxonomy of Viruses, and two additional species have 
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been identified. Phylogenetic analysis and the virus–
host relationship suggest that all 16 currently identified 
species of lyssaviruses can be divided into phylogroups. 
Phylogroup I comprises RABV, Duvenhage virus, Euro-
pean bat lyssavirus types 1 and 2 (EBLV-2), Australian bat 
lyssavirus, Aravan virus, Khujand virus, Irkut virus and 
Bokeloh bat lyssavirus, whereas Lagos bat virus, Mokola 
virus and Shimoni bat virus form phylogroup II [2, 3]. 
West Caucasian bat virus, Ikoma lyssavirus and Lleida 
bat lyssavirus may be representatives of possible new 
phylogroups [4–6]. Gannoruwa bat lyssavirus probably 
belongs to phylogroup I [7].
Human infections usually result from the bite of a rabid 
dog infected with RABV [1]. However, in a small num-
ber of cases, the infection results from contact with bats 
[8]. Two confirmed human cases caused by European 
bat lyssavirus type 2 (EBLV-2), one in Finland in 1985 [9, 
10] and one in the UK in 2002 [11] have been reported. 
EBLV-2 is known to associate with two closely related 
Myotis bat species, Daubenton’s (Myotis daubentonii) 
and pond bats (M. dascyneme). EBLV-2 has sporadically 
been isolated from Daubenton’s bats in the Netherlands 
[12], Switzerland [13], the UK [14], Finland [15, 16], 
Germany [17], Denmark [18] and Norway [19]. Finland 
was declared a rabies-free country by the OIE in 1991. 
Nevertheless, rabies can remain a residual risk to public 
health due to the natural circulation of EBLV-2 [15, 16]. 
Spillovers from chiropters to carnivores are not unusual, 
and at least two spillovers of RABV from bats to carni-
vore hosts have occurred, which have succeeded in being 
maintained through time [20, 21]. No spillover infections 
to other mammals than humans have been detected for 
EBLV-2. In experimental infections, EBLV-2 has been 
shown to cause fatal disease in foxes [22], sheep [23] and 
mice [24, 25]. European bat lyssavirus type 1 (EBLV-1), 
however, has been detected in natural infections of stone 
martens (Martes foina) [26], sheep [27] and domestic cats 
[28].
The assessment of rabies vaccine efficacy [1, 29, 30] is 
usually undertaken by immunisation and virus challenge 
using laboratory animals (potency test). The efficacy 
of vaccination can be indirectly assessed by measur-
ing antibodies from serum. Cellular immunity, how-
ever, is also important in clearing a virus infection [31]. 
Virus-neutralising antibody assays are used to verify that 
an immune response has occurred. An internationally 
accepted threshold titre of 0.5  IU/ml has been adopted 
[1]. However, it has been shown that vaccinated animals 
with low antibody levels have survived RABV challenge, 
indicating that other immune mechanisms also protect 
against rabies infection. On the other hand, according to 
Aubert [32], the presence of detectable neutralising anti-
bodies against rabies at the time of challenge does not 
indicate protection for all animals. Nevertheless, animals 
with neutralising antibodies at the time of challenge are 
significantly better protected against RABV than those 
without detectable virus neutralizing antibodies (VNA) 
[32, 33]. Information on the protection and cross-protec-
tion efficacy of rabies vaccines against all other lyssavi-
ruses under field conditions is still limited. Protection is 
inversely related to the genetic distance of the lyssavirus 
from RABV [34, 35].
The type of vaccine used, number of vaccinations, 
interval between vaccination and blood sampling, age at 
vaccination, sex, reproductive status, size and breed can 
all influence the antibody response of animals vaccinated 
against rabies [36–39]. In post-vaccination serological 
studies, the percentage of animals with inadequate titres 
has been 3.1–8.1% for dogs [36, 38, 40] and 2.85% for cats 
[36]. As many as 53% (95% CI 41–65%) of imported res-
cue dogs from Eastern Europe have been found to have 
inadequate titres after rabies vaccination [41].
Pre-exposure vaccination is recommended for people 
potentially at risk of rabies, such as veterinarians, labo-
ratory workers and bat handlers. People who work with 
rabies viruses in laboratories or vaccination produc-
tion facilities should have VNA tested every 6  months 
[1]. According to WHO recommendations, 0.5  IU/ml is 
a sufficient antibody level, considered to be proof of an 
adequate vaccination response, and a booster vaccina-
tion is recommended for levels lower than this. A series 
of booster vaccinations is also required after exposure to 
lyssavirus [1]. The same threshold titre is applied in dogs 
and cats to confirm a satisfactory response to vaccination 
prior to international travel. All vaccines currently avail-
able are based on RABV. According to studies conducted 
to investigate the cross-neutralisation of sera and cross-
protection in a mouse model against different lyssavi-
ruses, they offer variable cross-protection against other 
lyssaviruses [34, 35, 42–46]. However, there are no offi-
cial recommendations by WHO concerning whether the 
current procedure of pre-and post-exposure treatment 
would need to be modified for people who are exposed to 
other lyssaviruses than RABV.
The aim of this study was to assess the success of rabies 
vaccination measured by the antibody response in dogs 
and cats, as well as to study the factors influencing the 
inability of animals to produce a sufficient antibody 
response. In addition, the aim was to assess how well 
an RABV-based rabies vaccine, selected based on the 
ability to induce an antibody response in dogs and cats, 
affords protection in a mouse model against intracer-
ebral challenge with EBLV-2 isolated from a Finnish bat 
(FI-EBLV-2), as well as against challenge with RABV 
isolated from a Finnish raccoon dog (FIRD-RABV). We 
also examined the protection offered by a rabies vaccine 
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for humans and the correlation between VNA titres and 
cross-protection against EBLV-2 in mice.
Methods
Viruses
A Finnish EBLV-2 (FI-EBLV-2) isolate obtained from a 
Daubenton’s bat in 2009 (GenBank Accession Number 
JX129233) was used as the challenge virus. The original 
bat brain suspension was intracerebrally inoculated into 
eight newborn mice (ScaNmri suckling mice) with each 
mouse receiving 20 µl of the suspension. The brain sus-
pension from these eight newborn mice was subsequently 
inoculated into 4-week-old mice to amplify the virus and 
obtain the required quantity of virus stock to be used as 
the challenge virus in this study. RABV isolated from a 
Finnish raccoon dog (FIRD-RABV) (R1470/88) in 1988 
was also used in this study. The original archived brain 
passage had been kept at − 70 °C since 1990, and for this 
challenge study it was grown in the brain of 4-week-old 
mice to amplify the virus and obtain the required quan-
tity of virus stock.
Vaccination and virus challenge of mice
Three- to four-week-old NMRI mice (Harlan, NL; n = 20 
per challenge virus and n = 5 vaccine only) were vacci-
nated intra-peritoneally with 0.1  ml of vaccine diluted 
1:10 in physiological saline solution with a 16-mm nee-
dle. When the human vaccine (Rabies-Imovax®; Sanofi-
Pasteur MSD, France, batch G1391-4) was used, the mice 
were vaccinated either once (group a) or twice (group 
b) with a 2-week interval between the initial and the 
booster vaccination. When the animal vaccine  (Rabisin® 
vet; Merial, France, batch L374051) was used, the mice 
were vaccinated once. Vaccines were purchased from 
Helsinki University Pharmacy. The protocol was modi-
fied from the European Pharmacopoiea protocol [29]: the 
minimum lethal dose  (MLD50) for the intra-cranial chal-
lenge was determined according to protocol of European 
Pharmacopoeia [29] and 50  MLD50 was used. The mice 
were challenged intra-cranially with 30  µl of virus sus-
pension according to the procedure described by WHO 
[47] 28  days after vaccination. The mice were anesthe-
tized by inhalation anaesthesia using isoflurane, and they 
were given 0.05–0.1 mg/kg buprenorphine hydrochloride 
subcutaneously at the time of intra-cranial challenge. The 
back titration of five mice per group was set up with 50 
 MLD50, 5  MLD50 and 0.5  MLD50 of each virus. Five mice 
per vaccine were not challenged. The mice were moni-
tored twice per day for any clinical signs of rabies, and to 
minimize suffering they were killed when signs of rabies 
infection were obvious (weight loss, behavioural changes, 
neurological signs and paralysis) or when the observation 
period of 6 weeks had ended.
Serum was collected from the vaccinated mice prior 
to the challenge 21 or 22 days after the vaccination. The 
serum was collected from the lateral tail vein by appro-
priately trained personnel. The tail was first warmed and 
blood was collected with a 23-gauge needle. The target 
volume was 100 µl. At the end of the trial, the mice were 
euthanized either by the time they were showing clini-
cal signs or after the monitoring period. To confirm the 
presence of rabies infection, the brains of the mice were 
collected and a fluorescent antibody test (FAT) [30] was 
performed on the brain. Smears prepared from a sam-
ple of brain tissue were fixed in high-grade cold acetone, 
air dried and then stained with specific conjugate (FITC 
Anti-Rabies Monoclonal Globulin, Fujirebio Diagnos-
tics and Rabies Antinucleocapsid conjugate, Bio-Rad). 
FAT slides were then examined for specific fluorescence 
using a fluorescence microscope. The seroconversion of 
the vaccinated mice was analysed using the rapid fluores-
cent focus inhibition test RFFIT [30]. Five microlitres of 
sample was diluted 1:10. Serial dilutions of test sera were 
mixed with the challenge virus (CVS-11, ATCC VR-959) 
preparation and BHK-21 cells. Samples were fixed and 
stained with specific conjugate (FITC Anti-Rabies Mon-
oclonal Globulin, Fujirebio Diagnostics). Residual virus 
was detected using a standard fluorescence microscope. 
The serum neutralisation end-point titre was defined as 
the dilution factor of the highest serum dilution at which 
50% of the observed microscopic fields contained one or 
more infected cells. OIE/WHO human reference serum 
was used to convert the end point titre into IU/ml.
Serological analysis of dogs and cats
The antibody responses of dogs and cats were deter-
mined using the FAVN test [48]. This test involves the 
neutralisation of a constant amount of rabies virus CVS-
11 strain adapted to cell culture before inoculating cells 
susceptible to rabies virus (BHK-21 C13). The serum titre 
was the dilution at which 100% of the virus was neutral-
ised in 50% of the wells. This titre was expressed in IU/
ml by comparing it with the neutralising dilution of OIE 
serum of dog origin under the same test conditions.
Selection of dog and cat samples
This was a case–control study with a duration of 5 years. 
During 2009–2013, 10,793 serum samples from dogs 
(n =  10 071) and cats (n =  722) were sent to the Finn-
ish Food Safety Authority Evira for post-vaccination 
efficacy tests. Of these samples, 1055 dogs that had an 
antibody titre of <  0.5  IU/ml and for which submission 
data were available comprised the case group for dogs. 
An approximately similar number of dogs with submis-
sion data that had an antibody titre of ≥ 0.5 IU/ml were 
randomly assigned to the control group (n  =  1626). In 
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cats, only 25 had an antibody titre of < 0.5 IU/ml (cases), 
and a much larger number of cats that had antibody titre 
of  ≥  0.5  IU/ml were randomly assigned to the control 
group (n  =  241). Submission forms for these samples 
were evaluated. Three inactivated rabies vaccines were 
used for dogs and cats in Finland during 2009–2013: 
Wistar-G52 strain vaccine, BHK-21cell vaccine with Pas-
teur RIV strain and Flury LEP strain vaccine.
Statistical analysis
The 95% confidence intervals (CI) for valid percentages 
(excluding missing values) were calculated with Jef-
frey’s method [49] using EpiTools [50]. Statistical analy-
ses were performed using the statistical software SPSS 
22.0 (IBM SPSS Statistical Package version 22, USA). 
The outcome variable was failure to reach the required 
antibody level (0 for antibody level ≥  0.5  IU/ml, denot-
ing the ability to reach the required antibody level, and 
1 for <  0.5  IU/ml, denoting failure). Independent vari-
ables collated in the dataset were the vaccine used, age 
at vaccination, breed and size (only for dogs), gender, the 
number of vaccinations and the time from vaccination to 
sampling. Dogs were categorised into five different breed 
size groups based on their height (<  30  cm, 30–45  cm, 
46–60  cm,  >  60  cm and unknown). Furthermore, 277 
different dog breeds were originally categorized into 
10 groups by the Fédération Cynologique Internation-
ale. Animals were divided into two age groups: up to 
1  year and over 1  year old. Based on the time interval 
between vaccination and sampling, three groups were 
created: sampling less than 3  months after vaccination, 
3–6  months after vaccination and more than 6  months 
after vaccination. First, Fisher’s exact test and crude 
logistic regression analyses were performed to examine 
the pairwise associations between the outcome and each 
independent variable separately. Variables with P  ≤  0.2 
were included in the multivariable logistic regression 
analysis, with separate models for cats and dogs, and 
variables with Wald’s P < 0.05 were included in the final 
model. Correlations between independent variables were 
calculated with the Phi test (no important ones were 
found). A causal diagram was used to assess potential 
confounders; their impacts on the other variables in the 
model were verified, but none needed to be included in 
the models. Pairwise interactions were assessed. Since 
a significant interaction was found in dogs between the 
vaccine used and the age of the dog, two separate models 
were created: one for dogs up to 1 year old and another 
for older dogs. Additionally, for younger dogs, the time 
interval between vaccination and sampling was catego-
rized into two groups: up to or more than 6  months. 
The goodness of fit of the final model was assessed with 
the Omnibus test, Nagelkerke’s  R2 and the Hosmer and 
Lemeshow test, and by calculating the area under the 
curve (AUC).
Results
Results of the vaccine potency test
When challenged with FIRD-RABV, all of the vaccinated 
mice survived. When challenged with FI-EBLV-2, 80% of 
the vaccinated mice survived after vaccination with the 
veterinary vaccine. When mice were vaccinated with the 
human vaccine, 75–80% of the mice survived, depending 
on the booster (Table 1). All vaccinated mice developed 
sufficient to high VNA titres against RABV, ranging from 
0.5 to 128 IU/ml. The signs of rabies appeared 7–8 days 
post-infection with EBLV-2 and 6–7 days post-infection 
with RABV. Mice that succumbed after challenge with 
FI-EBLV-2 virus had a VNA titre of 2–64 IU/ml against 
RABV (individual results not shown). There were no sta-
tistically significant differences between the VNA titres 
of the mice that survived the challenge in comparison to 
those that succumbed after the challenge with EBLV-2 
(Fig.  1). Mice vaccinated twice with Rabies-Imovax® or 
once with  Rabisin® vet had significantly higher antibody 
titres than those vaccinated once with Rabies-Imovax® 
(P < 0.05) (Fig. 2).  
Results of the serological analysis of vaccinated dogs 
and cats
Of the 10,071 dog samples analysed during 2009–2013, 
1073 (10.7%; 95% confidence interval CI 10.1–11.3) had 
Table 1 Rabies vaccination protection following  an intra-
cranial challenge in mice
1 P value derived using Fisher’s exact test for the number of vaccinated and 
challenged mice that survived relative to the total and compared with the 50 
 MLD50 virus control mice
Total number 
of mice
Survival after challenge 
with
FIRD-RABV
n (%)
FI-EBLV-2
n (%)
Rabies Imovax, vac‑
cinated twice
20 20 (100) 16 (80)
P  value1 0.000 0.002
Rabies Imovax, vac‑
cinated once
20 ND 15 (75)
P  value1 0.005
Virus control 50  MLD50 5 0 (0) 0 (0)
Virus control 5  MLD50 5 2 (40) 2 (40)
Virus control 0.5  MLD50 5 4 (80) 4 (80)
Rabisin, vaccinated 
once
20 20 (100) 16 (80)
P  value1 0.002
Virus control 50  MLD50 5 0 (0) 0 (0)
Virus control 5  MLD50 5 2 (40) 2 (40)
Virus control 0.5  MLD50 5 3 (60) 4 (80)
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a VNA titre of <  0.5  IU/ml. Of the 722 cats analysed, 
only 25 (3.5%; 95% CI 2.3–5.0) had a VNA titre of 
< 0.5 IU/ml.
Risk factors for failure to produce sufficient antibody levels 
in dogs and cats
Descriptive data for the dogs and cats in the case–control 
study are provided in Tables 2 and 3. Younger dogs were 
associated with lower antibody titres (P < 0.05, data not 
shown). Since there was a significant interaction between 
the variables dog age and the vaccine used, two multivari-
able logistic regression models for dogs were constructed: 
one for dogs up to 1 year old and another for older dogs. 
For younger dogs, the Flury LEP vaccine was used sig-
nificantly more often than for older dogs (P < 0.05, data 
not shown). For both age groups, dogs vaccinated with 
the Flury LEP vaccine only and dogs vaccinated with the 
Pasteur RIV vaccine only had a significantly higher risk 
of failing to reach an antibody level of 0.5 IU/ml in com-
parison to dogs vaccinated with the Wistar-G52 vaccine 
only (Tables 4, 5). Additionally, for both age groups, vac-
cination with the Flury LEP vaccine only had the highest 
risk of failing to reach an antibody level of 0.5 IU/ml. In 
younger dogs, these risks were higher than in older dogs. 
In younger dogs, if the time between vaccination and 
sampling was over 3 months, the risk of failing to reach 
an antibody level of 0.5  IU/ml was significantly higher 
than if the time span was shorter. In older dogs, the risk 
was higher if the time was over 6 months. For older dogs 
(over 1  year) of a larger size (>  30  cm), the risk of fail-
ing to reach an antibody level of 0.5 IU/ml was greater. In 
younger dogs, those over 60 cm had a higher risk com-
pared to smaller dogs.
In cats, we observed no statistically significant dif-
ferences between the vaccines used (Table  6). However, 
there was a similar tendency towards a higher risk of fail-
ing to reach an antibody level of 0.5 IU/ml for vaccination 
with the Flury LEP vaccine only compared to vaccination 
with the Wistar-G52 vaccine only. Cats that were vac-
cinated at the age of up to 1 year old had a significantly 
higher risk of failing to reach an antibody level of 0.5 IU/
ml than cats vaccinated at an older age. Similarly to dogs, 
cats that were sampled for testing 3–6  months or over 
6  months after vaccination had a significantly higher 
risk of failing to reach an antibody level of 0.5  IU/ml 
than cats that had been sampled less than 3 months after 
vaccination.
Discussion
New lyssaviruses related to RABV have been discov-
ered, and it is possible that there may still be undetected 
bat lyssaviruses in many parts of the world. Bats do not 
often interact with people, but transmission of lyssavi-
ruses to humans and pets has been documented. Finland 
experienced a human death from EBLV-2 in 1985 [9, 
10], and better knowledge of the effectiveness of cross-
protection is therefore needed to predict the impact of 
Fig. 1 Comparison of VNA titers (ln) of the mice that survived the 
challenge (controls) and of the mice that succumbed after the chal‑
lenge with EBLV‑2 (cases). The interquartile range is the difference 
between the 75th and 25th percentiles and corresponds to the 
length of the box. The lines in the boxes represent the medians, 
the whiskers represent the minimum and maximum, unless there 
are values more than 1.5 times the interquartile range above 75th 
percentile, in which case it is the third quartile plus 1.5 times the 
interquartile range
Fig. 2 Comparison of VNA titers (ln) in three groups of mice vacci‑
nated with different vaccines or vaccination schemes. The interquar‑
tile range is the difference between the 75th and 25th percentiles 
and corresponds to the length of the box. The lines in the boxes 
represent the medians, the whiskers represent the minimum and 
maximum, unless there are values more than 1.5 times the interquar‑
tile range above 75th percentile, in which case it is the third quartile 
plus 1.5 times the interquartile range. Circles represent outliers that 
are > 2 box lengths below the 25th percentile
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rabies vaccination if exposed to infected bats, as EBLV-2 
appears to be enzootic at least in some areas in Finland 
[15, 16]. The immune response elicited by RABV-based 
rabies vaccines has been shown to be capable of cross-
protection against those lyssaviruses in phylogroup I, 
but not for those that do not belong to this phylogroup 
[42–45]. However, even though EBLV-2 belongs to the 
same phylogroup I as RABV, the protection induced by 
rabies vaccines has only been limited in an experimental 
virus challenge study in mice, even with the production 
of VNAs [34].
Table 2 Descriptive data on samples included in the statistical analysis of dog sera (n = 2681) tested for rabies antibody 
response after vaccination in Finland during 2009–2013
FCI group 1: Sheepdogs and Cattledogs (except Swiss Cattledogs), FCI group 2: Pinscher and Schnauzer—Molossoid and Swiss Mountain and Cattledogs, FCI group 
3: Terriers, FCI group 4: Dachshunds, FCI group 5: Spitz and primitive types, FCI group 6: Scent hounds and related breeds, FCI group 7: Pointing Dogs, FCI group 
8: Retrievers—Flushing Dogs—Water Dogs, FCI group 9: Companion and Toy Dogs, FCI group 10: Sighthounds
CI confidence interval, n number of cases
Variable Levels Antibody response
< 0.5 IU/ml (n = 1055)
Antibody response
≥ 0.5 IU/ml (n = 1626)
n % (95% CI) n % (95% CI)
Age at vaccination (year)
 ≤ 1 544 52.2 (49.2–55.2) 328 20.3 (18.4–22.3)
 > 1 498 47.8 (44.8–50.8) 1289 79.3 (77.7–81.6)
Gender
 Female 500 54.7 (51.5–57.9) 750 52.7 (50.1–55.3)
 Male 414 45.3 (42.1–48.5) 672 47.3 (44.7–49.9)
Number of vaccinations
 Once 941 89.2 (87.2–91.0) 1071 65.9 (63.5–68.1)
 Twice 99 9.4 (7.7–11.3) 433 26.6 (24.5–28.8)
 More than twice 15 1.4 (0.8–2.3) 122 7.5 (6.3–8.9)
Time btw vaccination and sampling (months)
 < 3 21 2.3 (1.5–3.4) 158 11.1 (9.6–12.9)
 3–6 335 36.8 (33.7–39.9) 459 32.3 (30.0–34.8)
 > 6 555 60.9 (57.7–64.1) 802 56.5 (53.9–59.1)
Vaccine used
 Only vaccine Wistar‑G52 53 7.3 (5.6–9.4) 229 22.1 (19.7–24.7)
 Only vaccine Pasteur RIV 298 41.3 (37.7–44.9) 387 37.4 (34.5–40.4)
 Only vaccine Flury LEP 315 43.6 (40.0–47.3) 233 22.5 (20.0–25.1)
 Other 56 7.8 (6.0–9.9) 186 18.0 (15.7–20.4)
FCI group
 FCI1 142 15.0 (12.8–17.4) 186 13.4 (11.7–15.2)
 FCI2 114 12.1 (10.1–14.2) 146 10.5 (9.0–12.2)
 FCI3 106 11.2 (9.3–13.3) 191 13.7 (12.0–15.6)
 FCI4 33 3.5 (2.5–4.8) 47 3.4 (2.5–4.4)
 FCI5 138 14.6 (12.4–16.9) 183 13.2 (11.5–15.0)
 FCI6 43 4.5 (3.4–6.0) 46 3.3 (2.5–4.3)
 FCI7 75 7.9 (6.3–9.8) 77 5.5 (4.4–6.8)
 FCI8 133 14.1 (12.0–16.4) 158 11.4 (9.8–13.1)
 FCI9 109 11.5 (9.6–13.7) 266 19.1 (17.1–21.3)
 FCI10 31 3.3 (2.3–4.6) 36 2.6 (1.8–3.5)
 No FCI group 22 2.3 (1.5–3.4) 55 4.0 (3.0–5.1)
Breed size (cm)
 < 30 178 19.2 (16.8–21.9) 434 32.3 (29.9–34.9)
 30–45 295 31.9 (28.9–34.9) 408 20.4 (28.0–32.9)
 46–60 208 22.5 (19.9–25.2) 267 19.9 (17.8–22.1)
 > 60 245 26.5 (23.7–29.4) 233 17.4 (15.4–19.5)
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VNAs are the main method of protection during rabies 
infection, and the role of cell-mediated and innate immu-
nity is poorly understood. Measuring the VNA titre is 
currently the most common way to assess the success 
of vaccination, and an internationally accepted thresh-
old of 0.5  IU/ml has therefore been adopted as an ade-
quate titre. In our study, all mice developed a sufficient 
VNA titre against RABV after vaccination, but mice that 
had VNA titres of 2–64 IU/ml, which is higher than the 
accepted threshold, succumbed after challenge with FI-
EBLV-2 virus, whereas all mice survived the challenge 
with FIRD-RABV. Due to this discrepancy between the 
VNA titres and cross-protection from the disease, people 
and animals need a post-exposure vaccination, regard-
less of their prior pre-exposure vaccination and antibody 
measurement result, if they are exposed to lyssaviruses. 
The intracranial route of infection was used because of 
the guidelines in the European Pharmacopoeia’s protocol. 
Pharmacopoeial methods are reference methods and the 
suitability of the method has been demonstrated. How-
ever, it should be noted that the intracranial exposure 
route used in our study is not the natural infection route.
Possible exposure to other lyssaviruses than RABV has 
especially raised concerns over whether RABV-based 
vaccines offer sufficient cross-protection and whether a 
higher cut-off for protection against EBLV-2 would be 
required. Studies have suggested that either higher serum 
VNA titres [34] or higher doses of rabies immunoglobu-
lins are required [45] in humans. There is marked individ-
ual variation in the comparative neutralisation patterns 
Table 3 Descriptive data on  samples included in  the sta-
tistical analysis of  cat sera (n =  266) tested for  the rabies 
antibody response after  vaccination in  Finland dur-
ing 2009–2013
CI confidence interval, n number of cases
Variable Levels Antibody 
response
< 0.5 IU/ml 
(n = 25)
Antibody response
≥ 0.5 IU/ml 
(n = 241)
n % (95% CI) n % (95% CI)
Age at vaccination (year)
 ≤ 1 12 48.0 (29.5–66.9) 47 19.6 (14.9–25.0)
 > 1 13 52.0 (33.1–70.5) 193 80.4 (75.0–85.1)
Gender
 Female 5 20.0 (8.1–38.4) 89 58.6 (50.6–66.2)
 Male 8 32.0 (16.4–51.5) 63 26.1 (20.9–31.9)
Number of vaccinations
 Once 24 96.0 (82.8–99.6) 194 80.5 (75.5–85.5)
 Twice 1 4.0 (0.4–17.2) 42 17.4 (13.0–22.6)
 More than twice 0 0.0 (0–9.5) 5 2.1 (0.8–4.5)
Time btw vaccination and sampling (months)
 < 3 1 5.3 (0.6–22.1) 78 42.2 (35.2–49.4)
 3–6 8 42.1 (22.3–64.1) 70 37.8 (31.1–45.0)
 > 6 10 52.6 (31.2–73.4) 37 20.0 (14.7–26.2)
Vaccine used
 Only vaccine Wistar‑G52 3 25.0 (7.6–52.9) 39 25.7 (19.2–33.0)
 Only vaccine Pasteur RIV 1 8.3 (0.9–32.8) 63 41.4 (33.8–49.4)
 Only vaccine Flury LEP 6 50.0 (24.3–75.7) 25 16.4 (11.2–22.9)
 Other 2 16.7 (3.6–43.6) 25 16.4 (11.2–22.9)
Table 4 Multivariable logistic regression results of risk factors for not reaching the antibody level of 0.5 IU/ml after vac-
cination against rabies in dogs up to 1 year old (n = 872) in Finland during 2009–2013
Na not applicable, CI confidence interval, other dogs vaccinated abroad with vaccines not available in Finland or with a combination of different vaccines
Independent variable Logistic regression coefficient B Wald’s
P value
Odds ratio (95% CI)
Vaccine
 Wistar‑G52 only Na Na 1
 Pasteur RIV only 2.049 0.000 7.8 (4.1–14.5)
 Flury LEP only 2.608 0.000 13.6 (7.0–26.2)
 D other 0.466 0.406 1.6 (0.5–4.8)
Breed size (cm)
 < 30 Na Na 1
 30–60 0.308 0.221 1.4 (0.8–2.2)
 > 60 1.159 0.000 3.2 (1.7–5.9)
Time btw vaccination and sampling (months)
 < 3 Na Na 1
 3–6 1.400 0.001 4.1 (1.8–9.1)
 > 6 1.508 0.000 4.5 (2.0–10.4)
Constant −2.907 0.000 0.055
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Table 5 Multivariable logistic regression results of risk factors for not reaching the antibody level of 0.5 IU/ml after vac-
cination against rabies in dogs older than 1 year (n = 1787) in Finland during 2009–2013
Na not applicable, CI confidence interval, other dogs vaccinated abroad with vaccines not available in Finland or with a combination of different vaccines
Independent variable Logistic regression coefficient B Wald’s
P value
Odds ratio (95% CI)
Vaccine
 Wistar‑G52 only Na Na 1
 Pasteur RIV only 0.926 0.000 2.5 (1.5–4.1)
 Flury LEP only 1.271 0.000 3.6 (2.2–5.9)
 Other 0.243 0.418 1.3 (0.7–2.3)
Breed size (cm)
 < 30 Na Na 1
 30–60 0.464 0.013 1.6 (1.1–2.3)
 > 60 0.823 0.000 2.3 (1.5–3.5)
Time btw vaccination and sampling (months)
 < 6 Na Na 1
 > 6 1.432 0.000 4.2 (2.8–6.3)
Constant −3.180 0.000 0.042
Table 6 Crude and multivariable logistics regression results of risk factors for not reaching the antibody level of 0.5 IU/
ml after vaccination against rabies in cats in Finland during 2009–2013
Na not applicable, CI confidence interval, other cats vaccinated abroad with vaccines not available in Finland or with a combination of different vaccines
Independent variable Logistic regression coefficient B Wald’s
P value
Odds ratio (95% CI)
In crude logistic regressions
 Vaccine (n = 164)
  Wistar‑G52 only Na 1 Na
  Pasteur RIV only −1.578 0.178 0.2 (0.0–2.1)
  Flury LEP only 1.138 0.130 3.1 (0.7–13.6)
  Other 0.039 0.967 1.0 (0.2–6.7)
 Age at vaccination (n = 265)
  < 1 year vs ≥ 1 year 1.332 0.002 3.8 (1.6–8.9)
 Time btw vaccination and sampling (n = 204) (months)
  < 3 Na 1 Na
  3–6 2.188 0.042 8.9 (1.1–73.1)
  > 6 3.048 0.004 21.1 (2.6–170.9)
In multivariable logistic regression (n = 159)
 Vaccine
  Wistar‑G52 only Na 1 Na
  Pasteur RIV only −1.090 0.378 0.3 (0.03–3.8)
  Flury LEP only 1.475 0.085 4.4 (0.8–23.5)
  Other 0.827 0.439 2.3 (0.3–16.6)
 Age at vaccination
  < 1 year vs ≥ 1 year 2.282 0.006 9.8 (1.9–48.8)
 Time btw vaccination and sampling (months)
  < 3 Na 1 Na
  3–6 1.615 0.19 5.0 (0.5–56.2)
  > 6 2.906 0.026 18.3 (1.4–235.3)
 Constant −5.439 0.000 0.004
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of human sera against different lyssaviruses [34, 42]. Our 
studies indicated that the RABV antibody level does not 
clearly correlate with protection against EBLV-2. There-
fore, laboratory personnel working with EBLV-2 should 
be regularly vaccinated and their antibody level should 
be monitored every 6 months, but it is still unclear what 
RABV antibody level would be protective. Therefore, 
booster vaccinations are recommended after possible 
exposure to lyssaviruses, and particular attention should 
be paid to the wound care after exposure. No laboratory 
accidents with other lyssaviruses than RABV have so far 
been reported.
Several factors influence the antibody level reached in 
an animal after vaccination, including the vaccine used, 
vaccine administration and the animal receiving the vac-
cine. Based on our studies, it is advisable that dogs that 
need a sufficient antibody test result due to international 
travel should be vaccinated twice with a rabies vaccine 
and then regularly receive a booster. Sihvonen et al. [40] 
demonstrated that a single vaccination of dogs with 
rabies vaccine induced moderate but short-term serocon-
version in 96.9% of dogs, but in 17% of dogs the antibody 
titre did not last for a whole year in a population that had 
not previously been vaccinated. If vaccinations are only 
performed by veterinarians in veterinary clinics and vac-
cines are stored according to the manufacturer’s instruc-
tions, this might have a positive effect on the outcome. 
Factors such as the consistency (virus strain, cell culture 
and adjuvants) of the vaccine influence the vaccination 
response.
The difference between the proportions of dogs 
(around 11%) and cats (around 3%) that failed to reach 
the antibody level of 0.5  IU/ml might be caused by dif-
ferences in genetic variation within the two species, as 
pedigree dogs are purebred, whereas the majority of cats 
in our study material were mixed breeds. The key genetic 
elements of immune responsiveness lie within the genes 
of the major histocompatibility complex (MHC). It has 
been suspected that cats have more limited diversity in 
immune response genes than dogs, but recent research 
has demonstrated similar variation in the MHC in cats 
to that found in dogs [51]. In our study, there was a sig-
nificant difference in the ability of different vaccines to 
induce the antibody level of 0.5  IU/ml in dogs. This has 
also been reported in earlier studies [36–39], and may be 
due to differences in the immunogenicity of the vaccines 
or the potency of the vaccine batches. Moreover, veteri-
narians should note that there are significant differences 
between vaccines in their ability to induce an immune 
response. This difference between the vaccines was not 
statistically significant in cats, perhaps due to the type 
two error of an insufficient sample size, since there were 
so few (n = 25) failures to reach the threshold of 0.5 IU/
ml in cats.
The time between vaccination and sampling was a sig-
nificant risk factor for both dogs and cats failing to reach 
the threshold of 0.5  IU/ml. The antibody level peaks 
at slightly different times after vaccination with differ-
ent vaccines, and the level starts to decline afterwards 
[37]. Larger dogs had a greater risk of failing to reach 
the required antibody level. Increasing the dose would 
not probably be a solution, since it has been shown 
that if there is a sufficient antigen to create a response, 
larger doses will not increase antibody production. Ken-
nedy et  al. [37] suggested that larger breeds might have 
deeper sub-cutaneous fat, which could reduce the level 
of the antibody response. The breed might also be a fac-
tor, not just the size of the dog, since even though most 
failures to reach the anticipated antibody level occurred 
in larger breeds, some smaller breeds had significant test 
failure rates [52]. Specific dog breeds have a genetically 
determined immune function, and a study has confirmed 
breed-specific serological response patterns to vaccina-
tion. The high interbreed and relatively low intrabreed 
variation in MHC alleles and haplotypes could provide 
an explanation for the reports of interbreed variation in 
immune responses to vaccines [53]. The higher risk of 
failing to reach 0.5  IU/ml for dogs and cats aged up to 
1 year old could be due to the administration of vaccines 
before the animals had reached full immunocompetency, 
or due to maternal antibodies [36, 39].
In rabies-free countries, the rabies vaccination coverage 
of cats and dogs is likely to be lower than in rabies enzo-
otic countries. Cats, especially in the countryside, often 
freely roam outside and are therefore able to encounter 
wildlife, consequently being at greater risk of exposure 
to rabid animals, and especially to bats, than dogs. Host 
switching of lyssaviruses from bats to mammals has suc-
cessfully occurred in history [20, 21]. Natural spillover 
of EBLV-2 to other mammals than humans has not been 
demonstrated. Only a small proportion of cats failed to 
reach the required antibody level in our study, but the 
vaccination coverage of cats against rabies is assumed to 
be low in many rabies-free countries, at least in Finland. 
Based on the number of vaccination doses sold, we esti-
mated that about 10–20% of 700,000 Finnish cats have 
been vaccinated against rabies. The rabies vaccination 
coverage is higher for dogs, estimated at around 40–65% 
based on the rabies vaccine sales in Finland.
We demonstrated in the mouse model challenge that 
an RABV-based animal vaccine offers cross-protection 
against challenge with the FI-EBLV-2 strain isolated from 
a bat. Therefore, it is recommended that even in rabies-
free countries, dogs and cats that come into contact with 
lyssavirus and infected bats should be vaccinated against 
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rabies. Booster vaccination is recommended for dogs, 
especially of large breeds. Moreover, veterinarians should 
pay attention to the choice of vaccine used.
Conclusions
A veterinary RABV-based rabies vaccine, selected based 
on the ability to induce the best antibody response of the 
vaccines compared for dogs and cats in this study, offered 
cross-protection against EBLV-2 challenge in a mouse 
model in comparison with a challenge with RABV. Our 
mouse model provided an indication that the RABV anti-
body level and protection against EBLV-2 are not clearly 
correlated, and this most probably reflects the situation 
in other mammals and humans. There was a statistically 
significant difference in VNA titres between three groups 
of mice vaccinated with different vaccines or vaccination 
schemes. Approximately 11% of vaccinated dogs tested 
from the field failed to have an antibody titre of 0.5  IU/
ml or more. By comparison, only a small proportion of 
cats failed to reach the required antibody level. Booster 
vaccination and vaccinating dogs and cats encountering 
bats is recommended, since vaccination also offers cross-
protection against EBLV-2.
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